ArticleEClinicalMedicine2026

Efficacy and safety of liposomal irinotecan plus nimotuzumab in immune checkpoint inhibitor-refractory recurrent or metastatic nasopharyngeal carcinoma: a single-arm, open-label, phase II trial.

Shuiqing He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.